Engineered immune cells take on Hard-to-Treat ovarian and endometrial cancers
Disease control
Not yet recruiting
This early-phase trial tests a one-time treatment called OPB-201, where a patient's own immune cells are modified in a lab to better recognize and attack cancer cells that carry a protein called PRAME. The study will enroll 30 adults with recurrent endometrial cancer or platinum-…
Phase: PHASE1 • Sponsor: Outpace Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC